Xeris Pharmaceuticals (NASDAQ:XERS) issued its earnings results on Wednesday, March 6th. The company reported ($0.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by ($0.04), Fidelity Earnings reports. The firm had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.10 million.
Shares of Xeris Pharmaceuticals stock opened at $9.54 on Friday. The company has a market capitalization of $260.86 million and a PE ratio of -1.91. Xeris Pharmaceuticals has a 52 week low of $8.67 and a 52 week high of $27.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 11.59 and a quick ratio of 11.59.
A number of research firms have commented on XERS. Zacks Investment Research lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 12th. ValuEngine lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. Finally, Mizuho restated a “buy” rating and set a $27.00 target price on shares of Xeris Pharmaceuticals in a research report on Tuesday, December 4th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $23.60.
In related news, insider James E. Flynn sold 7,038 shares of the stock in a transaction that occurred on Tuesday, January 29th. The stock was sold at an average price of $15.12, for a total transaction of $106,414.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Steven Prestrelski sold 15,720 shares of the stock in a transaction that occurred on Wednesday, December 26th. The shares were sold at an average price of $15.82, for a total value of $248,690.40. The disclosure for this sale can be found here. Over the last three months, insiders bought 620,500 shares of company stock valued at $6,178,600 and sold 159,250 shares valued at $2,452,644.
A hedge fund recently raised its stake in Xeris Pharmaceuticals stock. Geode Capital Management LLC lifted its stake in Xeris Pharmaceuticals Inc (NASDAQ:XERS) by 23.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 82,692 shares of the company’s stock after acquiring an additional 15,459 shares during the period. Geode Capital Management LLC owned approximately 0.40% of Xeris Pharmaceuticals worth $1,405,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 51.68% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Xeris Pharmaceuticals (NASDAQ:XERS) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS” was originally published by Fairfield Current and is the property of of Fairfield Current. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.fairfieldcurrent.com/news/2019/03/15/xeris-pharmaceuticals-xers-issues-quarterly-earnings-results-misses-expectations-by-0-04-eps.html.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Article: 12b-1 Fees
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.